Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplitude Inc (AMPL) vs Zoetis Inc (ZTS) Price & Performance

Amplitude IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Amplitude Inc vs Zoetis Inc — how do they compare? Amplitude Inc trades at $9.55 (market cap $1.22B), while Zoetis Inc trades at $75.07 (market cap $31.68B). The key difference: Zoetis Inc is far larger — about 26× Amplitude Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.

AMPLZTS
Market Cap
$1.22B$31.68B
Sector
TechnologyHealth
52-Week High
$13.04$156.76
52-Week Low
$5.61$71.91
Enterprise Value
$1.05B$38.97B
Dividend Yield
2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplitude Inc

AMPL trades at $9.18, down 2.13% over the past day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, reaching $343.21M in 2025, yet the company remains unprofitable with a net income margin of -25.11%. Analyst consensus is bullish with a $9.25 price target, though recent news includes multiple law firm fraud investigations and a Bank of America downgrade citing profitability concerns.

The outlook hinges on AMPL's ability to translate robust revenue growth into profitability amid competitive pressures. Investment opportunity lies in potential margin expansion and market share gains, but risks include ongoing legal scrutiny, execution challenges, and persistent negative cash flows. The stock's near-term direction will likely be driven by upcoming earnings results and clarity on the fraud allegations.

Zoetis Inc

Zoetis (ZTS) trades at $75.56, up 0.64% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 28.03% net margins and 67.75% ROE, supported by consistent revenue growth to $9.47B in 2025. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with a $101.43 price target. Legal developments include multiple securities class action notices with July 27, 2026 deadlines.

ZTS presents a mixed outlook with strong fundamental performance offset by technical weakness and legal overhangs. The stock trades at attractive valuations (P/E 12.39) with significant upside to analyst targets, but investors face near-term volatility from the class action proceedings and recent earnings miss. Long-term growth prospects remain solid given the company's market leadership in animal health.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplitude Inc

Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.

Read more on AMPL

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS